InVivo Therapeutics Holdings Corp announces the publication of a manuscript in the journal Biomaterials describing preclinical findings regarding the Neuro-Spinal Scaffold.

The publication studied the clinical feasibility, timing, and indication for scaffold implantation in a preclinical setting, and supports the scientific foundation for clinical investigation of biomaterial scaffold implantation into the human injured spinal cord.

“We are very pleased to see the preclinical findings published in a high impact journal that supports and encourages the current clinical investigation of the Neuro-Spinal Scaffold as a potential treatment option in acute spinal cord injuries,” says Richard Toselli, MD, president and chief executive officer of InVivo Therapeutics, headquartered in Cambridge, Mass, in a media release.

[Source(s): InVivo Therapeutics Holdings Corp, Business Wire]